UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050579
Receipt number R000057307
Scientific Title Prospective obserbational study of diabetes using new classifications by HLA, SNPs and biomarkers
Date of disclosure of the study information 2023/03/14
Last modified on 2024/03/17 12:32:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective obserbational study of diabetes using new classifications by HLA, SNPs and biomarkers

Acronym

Ehime Genome Study

Scientific Title

Prospective obserbational study of diabetes using new classifications by HLA, SNPs and biomarkers

Scientific Title:Acronym

Ehime Genome Study

Region

Japan


Condition

Condition

type 1 diabetes mellitus, type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases, kidney diseases, dementia, sarcopenia, frailty, and periodontal disease

Classification by specialty

Medicine in general Cardiology Endocrinology and Metabolism
Nephrology Geriatrics Obstetrics and Gynecology
Laboratory medicine Dental medicine Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

The aim of this study is to investigate new classifications for diabetes defined by HLA, SNPs, islet-specific autoantibodies, C-peptide, and other biomarkers.

Basic objectives2

Others

Basic objectives -Others

The other objective is to clarify the association between the factors of the new classifications and onset of diabetes and its complications, cardiovascular diseases, kidney diseases, dementia, sarcopenia, frailty, and periodontal disease in the prospective study.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Onset or progression of diabetes mellitus, cardiovascular diseases, kidney diseases, dementia, sarcopenia, frailty, and periodontal disease

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >

Gender

Male and Female

Key inclusion criteria

1) About 2500 patients with diabetes: inpatients and outpatients in Ehime university hospital and the affiliated hospitals*, and the residents in Toon city (Ehime, Japan) who are participated in the Toon Genome Study**
2) About 2500 participants without diabetes: the residents in Toon city (Ehime, Japan) who are participated in the Toon Genome Study**

* The patients were recruited as a part of the Ehime Study since 1998
** This study commenced in 2009

Key exclusion criteria

1) Patients who do not consent to the study
2) Patients who are judged inappropriate for the study by a doctor

Target sample size

5000


Research contact person

Name of lead principal investigator

1st name Haruhiko
Middle name
Last name Osawa

Organization

Ehime University Graduate School of Medicine

Division name

Diabetes and Molecular Genetics

Zip code

791-0295

Address

454 Shitsukawa, Toon, Ehime, Japan

TEL

089-960-5647

Email

harosawa@m.ehime-u.ac.jp


Public contact

Name of contact person

1st name Haruhiko
Middle name
Last name Osawa

Organization

Ehime University Graduate School of Medicine

Division name

Diabetes and Molecular Genetics

Zip code

791-0295

Address

454 Shitsukawa, Toon, Ehime, Japan

TEL

089-960-5647

Homepage URL


Email

harosawa@m.ehime-u.ac.jp


Sponsor or person

Institute

Ehime University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ehime University Hospital

Address

454 Shitsukawa, Toon, Ehime, Japan

Tel

089-960-5171

Email

rinri@m.ehime-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 03 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 01 Month 01 Day

Date of IRB

2019 Year 12 Month 22 Day

Anticipated trial start date

2020 Year 01 Month 01 Day

Last follow-up date

2030 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The Toon Genome Study has conducted first survey (2009-2012), second survey (2014-2018), third survey (2019-2022) and fourth survey (2024-). This study has planned anual checkup.


Management information

Registered date

2023 Year 03 Month 14 Day

Last modified on

2024 Year 03 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000057307


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name